(NASDAQ: TSBX) Turnstone Biologics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.
Turnstone Biologics's earnings in 2025 is -$70,837,000.On average, 1 Wall Street analyst forecast TSBX's earnings for 2025 to be -$15,965,838, with the lowest TSBX earnings forecast at -$15,965,838, and the highest TSBX earnings forecast at -$15,965,838. On average, 1 Wall Street analyst forecast TSBX's earnings for 2026 to be -$11,800,837, with the lowest TSBX earnings forecast at -$11,800,837, and the highest TSBX earnings forecast at -$11,800,837.
In 2027, TSBX is forecast to generate -$7,635,836 in earnings, with the lowest earnings forecast at -$7,635,836 and the highest earnings forecast at -$7,635,836.